Reliability of Serum Metabolite Concentrations over a 4-month Period Using a Targeted Metabolomic Approach
Overview
Authors
Affiliations
Metabolomics is a promising tool for discovery of novel biomarkers of chronic disease risk in prospective epidemiologic studies. We investigated the between- and within-person variation of the concentrations of 163 serum metabolites over a period of 4 months to evaluate the metabolite reliability expressed by the intraclass-correlation coefficient (ICC: the ratio of between-person variance and total variance). The analyses were performed with the BIOCRATES AbsoluteIDQ™ targeted metabolomics technology, including acylcarnitines, amino acids, glycerophospholipids, sphingolipids and hexose in 100 healthy individuals from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study who had provided two fasting blood samples 4 months apart. Overall, serum reliability of metabolites over a 4-month period was good. The median ICC of the 163 metabolites was 0.57. The highest ICC was observed for hydroxysphingomyelin C14:1 (ICC = 0.85) and the lowest was found for acylcarnitine C3:1 (ICC = 0). Reliability was high for hexose (ICC = 0.76), sphingolipids (median ICC = 0.66; range: 0.24-0.85), amino acids (median ICC = 0.58; range: 0.41-0.72) and glycerophospholipids (median ICC = 0.58; range: 0.03-0.81). Among acylcarnitines, reliability of short and medium chain saturated compounds was good to excellent (ICC range: 0.50-0.81). Serum reliability was lower for most hydroxyacylcarnitines and monounsaturated acylcarnitines (ICC range: 0.11-0.45 and 0.00-0.63, respectively). For most of the metabolites a single measurement may be sufficient for risk assessment in epidemiologic studies with healthy subjects.
Barko P, Jambhekar A, Swanson K, Ridgway M, Williams D PLoS One. 2024; 19(5):e0303500.
PMID: 38814947 PMC: 11139287. DOI: 10.1371/journal.pone.0303500.
Winkvist A, Johansson I, Ellegard L, Lindqvist H Nutr J. 2024; 23(1):29.
PMID: 38429740 PMC: 10908051. DOI: 10.1186/s12937-024-00929-1.
Oosterwegel M, Ibi D, Portengen L, Probst-Hensch N, Tarallo S, Naccarati A Environ Sci Technol. 2023; 57(34):12752-12759.
PMID: 37582220 PMC: 10469440. DOI: 10.1021/acs.est.3c03233.
Characterisation of Fasting and Postprandial NMR Metabolites: Insights from the ZOE PREDICT 1 Study.
Bermingham K, Mazidi M, Franks P, Maher T, Valdes A, Linenberg I Nutrients. 2023; 15(11).
PMID: 37299601 PMC: 10255657. DOI: 10.3390/nu15112638.
NMR-Metabolomics Reveals a Metabolic Shift after Surgical Resection of Non-Small Cell Lung Cancer.
Derveaux E, Geubbelmans M, Criel M, Demedts I, Himpe U, Tournoy K Cancers (Basel). 2023; 15(7).
PMID: 37046788 PMC: 10093525. DOI: 10.3390/cancers15072127.